Company intelligence / Profile preview

Sys Apolo

Cambridge, Cambridgeshire, UKglobaltenders.com ↗

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Apollo Therapeutics has over 20 active therapeutic programs with a diversified portfolio approach. Most assets are in discovery or preclinical stages, with some progressing into clinical development. The company emphasizes strong experimental validation using human biology/geenetics and collaborates closely with top-tier academic institutions. No specific late-stage clinical results have been published as of June 2025

Therapeutic areas: OncologyMetabolic DisordersImmunology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Biotech

Partnerships

University of CambridgeImperial College LondonUniversity College LondonKing’s College LondonThe Institute of Cancer Research

Beyond the preview

Go deeper on Sys Apolo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sys Apolo.

Explore the full profile